Lipolytic Effects of B-Type Natriuretic Peptide1–32 in Adipose Tissue of Heart Failure Patients Compared With Healthy Controls  by Polak, Jan et al.
Journal of the American College of Cardiology Vol. 58, No. 11, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Lipolytic Effects of B-Type Natriuretic Peptide1–32
in Adipose Tissue of Heart Failure Patients
Compared With Healthy Controls
Jan Polak, MD, PHD,*‡§ Martin Kotrc, MD,* Zuzana Wedellova, MD,§ Antonin Jabor, MD, PHD,*
Ivan Malek, MD, PHD,* Josef Kautzner, MD, PHD,* Ludmila Kazdova, PHD,†
Vojtech Melenovsky, MD, PHD*
Prague, Czech Republic; and Baltimore, Maryland
Objectives Our goal was to examine the role of B-type natriuretic peptide (BNP) in lipolysis regulation in heart failure (HF)
patients.
Background Enhanced adipose tissue lipolysis can contribute to myocardial lipid overload, insulin resistance, and cachexia in
advanced HF. Natriuretic peptides were recently recognized to stimulate lipolysis in healthy subjects.
Methods Ten nondiabetic HF patients (New York Heart Association functional class III, 50% nonischemic etiology) and
13 healthy subjects (control subjects) of similar age, sex, and body composition underwent a microdialysis study
of subcutaneous abdominal adipose tissue. Four microdialysis probes were simultaneously perfused with
0.1 M BNP1–32, 10 M BNP1–32, 10 M norepinephrine (NE) or Ringer’s solution. Outgoing dialysate glycerol
concentration (DGC) was measured as an index of lipolysis.
Results Spontaneous lipolysis was higher in HF patients compared with control subjects (DGC: 189  37 mol/l vs.
152  35 mol/l, p  0.01). Response to NE was similar (p  0.35) in HF patients and control subjects (DGC
increase of 1.7  0.2-fold vs. 1.7  0.4-fold). BNP1–32 10 M markedly increased lipolysis in both HF patients
and control subjects (DGC increase of 2.8  0.5-fold vs. 3.2  0.3-fold), whereas the response to 0.1 M
BNP1–32 was more pronounced in HF patients (p  0.02). In HF patients, spontaneous lipolysis positively corre-
lated with insulin resistance and the response to BNP1–32 negatively correlated with adiposity.
Conclusions BNP1–32 exerts strong lipolytic effects in humans. Despite marked elevation of plasma immunoreactive BNP, the
responsiveness of adipose tissue to BNP1–32 is not attenuated in HF, possibly reflecting a deficiency of endoge-
nous bioactive BNP. Lipolytic effects of BNP can contribute to excessive fatty acid mobilization in advanced
HF. (J Am Coll Cardiol 2011;58:1119–25) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.042A chronic heart failure (HF) state triggers a neuroendocrine
response that stimulates the release of free fatty acids
(FFAs) from adipose tissue (AT) (1). Although FFAs are
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accepted May 31, 2011.the major substrate for cardiac metabolism, persistently
increased FFA efflux from AT might have adverse effects on
cardiac function (2) by impairing insulin sensitivity (3),
diminishing cardiac efficiency (4), and contributing to myo-
cardial lipotoxicity (5–7). Enhanced lipolysis also contrib-
utes to body weight loss and cardiac cachexia, which are
linked with a particularly poor outcome in HF (2,8–10).
Increased adrenergic-fatty acid load in HF has been sug-
gested as a potential therapeutic target (11–14).
See page 1126
Mechanisms of increased AT lipolysis in HF patients are
incompletely understood. Lipolysis in HF patients is stim-
ulated by increased catecholamines (15) and tumor necrosis
factor- (16). Recently, it was recognized that natriuretic
peptides (NPs) are also capable of stimulating lipolysis in
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of atrial natriuretic peptide (ANP)
was first suggested by in vitro
experiments (19,20) and subse-
quently confirmed by in vivo
studies by our and other groups
(20,21). ANP appears to be a
major regulator of lipolysis dur-
ing prolonged exercise (22) in
healthy subjects, surpassing the
contribution of catecholamines
(14,23). ANP is also responsible
for the regulation of residual li-
polysis in situations of pharma-
cological beta-adrenergic block-
ade (2,23). Much less is known
about the role of B-type natriuretic peptide (BNP) in
lipolysis regulation. Importantly, no studies have examined
the lipolytic role of BNP in HF patients, despite important
links between NP system activation, enhanced lipolysis, and
possible progression of HF.
BNP is released from the heart as inactive pro-BNP1–108
in response to increased wall stress (6,9,24) and is then cleft
into the bioactive form BNP1–32 by specific proteases
9,10,14,17). Despite the fact that circulating immunoreac-
ive BNP (iBNP) is typically increased in HF and serves as
hallmark of the disease (25,26), the functional effects of
NP on target tissues are influenced by abnormal process-
ng/decreased generation of bioactive BNP species (active-
NP deficiency) or by attenuated tissue response (BNP
esistance). Which of these 2 mechanisms prevail in AT of
F patients is currently unknown; however, this question
an be addressed by examining in vivo lipolytic responses by
he administration of exogenous bioactive BNP1–32. BNP-
mediated lipolysis would be attenuated if the latter mecha-
nism prevails or preserved if the former mechanism is
operational.
The aim of this study was to examine the effects of
BNP1–32 on regulation of lipolysis in vivo and to compare
ealthy subjects with advanced HF patients. We used the
nique technique of microdialysis, which allows tissue
elivery of pharmacological substances into subcutaneous
T with simultaneous sampling of extracellular fluid for
etabolite analyses.
ethods
ubjects. Men with symptomatic HF (n  10) were
recruited at the Cardiology Department of IKEM, Prague,
Czech Republic. HF was defined by Framingham criteria as
a history of HF hospitalization, documented systolic dys-
function (left ventricular ejection fraction 35%), and
persistent symptoms (New York Heart Association func-
tional class of II or higher for 3 months). Importantly, we
excluded patients with diabetes mellitus and hemodynamic
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
AT  adipose tissue
BNP  B-type natriuretic
peptide
DGC  dialysate glycerol
concentration
FFA  free fatty acid
HF  heart failure
iBNP  immunoreactive
B-type natriuretic peptide
NP  natriuretic peptideinstability, infection, severe renal failure or anemia (creati- lnine 300 mol/l, hemoglobin 100 g/l), endocrine dis-
ease, restrictive or hypertrophic cardiomyopathy. HF etiol-
ogy was coronary artery disease in 50% and nonischemic in
the rest. All patients were treated with furosemide (54  8
mg/day), 9 with beta-blockers and 7 with angiotensin-
converting enzyme inhibitors or angiotensin receptor antag-
onists. Healthy male controls (n  13), free of any disease
or medication, were recruited by advertisement. All subjects
were nonsmokers. The study was approved by the local
ethics committee, and all subjects signed informed consent.
Clinical measurements. Symptoms were quantified using
a Minnesota Living With Heart Failure Questionnaire,
body composition was assessed using dual-energy X-ray
absorptiometry (Lunar Prodigy, GE Healthcare, Wauke-
sha, Wisconsin), and skinfold thickness was measured with
Best’s calipers (nondominant triceps, biceps, subscapular,
and supra-iliac region). Patients were weighed (Omron
HBF510W, Tokyo, Japan), underwent cardiac ultrasonog-
raphy (Vivid7, GE Healthcare), and their height was
measured with a stadiometer. For biochemical tests, venous
blood samples were obtained after an overnight fast and
plasma was stored at 80°C until analysis. An oral glucose
tolerance test was performed on a separate day (75 g of
glucose/300 ml of water), with sampling of venous blood at
0, 30, 60, and 120 min. All variables were collected within 5
ays from the microdialysis experiment.
icrodialysis protocol. Microdialysis is a mini-invasive
ethod evaluating AT metabolism in vivo (27). Semiper-
eable membrane probes are perfused (with or without
harmacological substances) at low flow rates until equilib-
ium is established between interstitial tissue fluid and
ialysate solution in the probe. Glycerol released from
dipocytes after triglyceride hydrolysis is used as a lipolysis
arker. Microdialysis perfusions with 2 different concen-
rations of BNP1–32 (0.1 M and 10 M) were based on
previous in vitro data (28) showing maximum lipolytic
response with 10 M and 50% of maximum effect with a
0.1-M concentration (2,8,29,30). The subjects entered the
research unit at 8:00 AM after an overnight fast. All heparin
as withheld for more than 24 h before tests. At 8:30 AM,
4 microdialysis probes (20,000-kDa cutoff, CMA Microdi-
alysis, Stockholm, Sweden) were inserted in the subcutane-
ous abdominal AT. The probes were connected to a
microperfusion pump (Harvard Apparatus, Les Ulis,
France) and perfused with Ringer’s solution (Baxter,
Prague, Czech Republic). Ethanol (1.7 g/l) was added to the
perfusate to estimate changes in the blood flow, as described
previously (9,10,14). The first probe was perfused with
Ringer’s solution (control probe), the second probe with
10 M norepinephrine (Leciva, Prague, Czech Republic),
the third probe with 10 M of human recombinant
NP1–32 (nesiritide-Noratak, Janssen-Cilag, Baar, Switzer-
and) and the fourth probe with 0.1 M BNP1–32. The
tudy consisted of 80-min baseline sampling and 60 min of
harmacological stimulation. Dialysate samples were col-ected at 20-min intervals at a flow rate of 1 l/min
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September 6, 2011:1119–25 BNP-Induced Lipolysis in Heart Failurethroughout the experiments. The dialysate glycerol concen-
tration (DGC) was measured as a marker of lipolysis.
To evaluate the relative recovery of microdialysis probes
(a parameter describing permeability characteristics of the
membrane), 4 probes were submerged in a vial containing
0.1 M BNP1–32 dissolved in saline solution. After 3-h
quilibration, probes were perfused with saline solution and
.1% albumin at flow rates 0.5, 1, 2, 3.5, and 5 l/min.
BNP1–32 was measured in dialysate and in surrounding
BNP1–32 solution and log-transformed concentrations were
lotted against perfusion rates to calculate the relative
ecovery at each perfusion rate. This experiment demon-
trated a relative recovery of 20  2% for BNP1–32 at
perfusion rate 1 l/min.
Biochemical analysis. The iBNP concentrations were
measured by chemiluminescent microparticle immunoassay
(Architect BNP, Abbott Laboratories, Abbott Park, Illi-
Anthropometric and Clinical Parameters of HF PTable 1 Anthropometric and Clinical Parame
HF Patie
Age, yrs 56.0 3.0
NYHA functional class 3.0 2.8
MLHFQ score 55 7
Systolic/diastolic BP, mm Hg 102 8/6
Heart rate, beats/min 76.3 4.6
Anthropometric variables
Body mass index, kg/m2 25.8 1.1
Waist circumference, cm 96.6 2.8
Skinfold thickness, mm 32.9 5.1
Fat mass, DEXA, kg 25.6 2.6
Lean mass, DEXA, kg 59.4 3.0
Echocardiography
LV end-diastolic diameter, mm 75.5 3.1
LV ejection fraction, % 23.6 1.1
RV dysfunction grade (0–4) 1.5 0.3
Mitral regurgitation grade (0–4) 2.2 0.4
Values are mean  SD. *p value for comparison of HF and control gr
BP  blood pressure; DEXA  dual-energy X-ray absorptiometry; HF
Failure Questionnaire; NYHA  New York Heart Association; RV  rig
Biochemical and Insulin Sensitivity ParametersTable 2 Biochemical and Insulin Sensitivity
HF G
BNP, pg/ml 793.2 (549.
BNP, pmol/l 174.5 (120
Fasting glucose, mmol/l 5.2
Fasting insulin, mIU/l 8.9
HOMA-IR 2.1
HbA1c, % 4.2
Oral glucose tolerance test
Glucose AUC, mmol/l/120 min 6,056
Insulin AUC, mIU/ml/120 min 869.6
Glucose120 min, mmol/l 6.6
Insulin120 min, mIU/l 46.5
Values are median (interquartile range) or mean  SEM. *p value for
AUC area under the curve; BNP B-type natriuretic peptide; HbA1c glyc
model assessment of insulin resistance.nois), insulin by IRMA assay (Immunotech, Prague, Czech
Republic), FFA by immunoturbidimetry (Wako, Rich-
mond, Virginia), and glycerol by Randox Glycerol Kit
(Randox Laboratories Ltd., Antrim, United Kingdom).
Statistical analysis. Statistical analysis was performed us-
ing SPSS version 13.0 for Windows (SPSS Inc., Chicago,
Illinois). The response of AT to pharmacological perfusions
was evaluated in the HF and control groups separately using
Student’s paired t test. Differential responses to BNP1–32,
norepinephrine, or Ringer’s solution perfusion between
groups were evaluated using an ordinary t test. Between-
group differences in anthropometric and biochemical vari-
ables (Tables 1 and 2) were evaluated using the Mann-
Whitney test. Associations between variables were
investigated using the Spearman method. Data are pre-
sented as mean  SEM unless stated otherwise. A level of
p  0.05 was considered statistically significant.
ts and Control Groupof HF Patients and Control Group
Control Group p Value*
48.0 1.5 0.016
1 0 0.001
0.8 0.8 0.001
113 10/79 7 0.05/0.013
71.9 1.7 0.34
28.0 0.7 0.041
100.0 1.8 0.284
41.1 4.3 0.192
25.7 1.7 0.905
62.4 1.5 0.552
50.7 1.3 0.001
60.0 0.0 0.001
0 0 0.001
0.7 0.2 0.008
ann-Whitney test). Skinfold thickness is a sum of 4 skinfolds.
t failure; LV  left ventricular; MLHFQ  Minnesota Living With Heart
icular.
Patients and Control Groupmeters of HF Patients and Control Group
Control Group p Value*
8.6) 27.6 (19.9–36.3) 0.001
.5) 6.1 (4.4–8.0)
5.5 0.1 0.064
9.4 1.2 0.595
2.4 0.3 0.645
3.7 0.1 0.006
6,057 2,229 0.268
785.6 118.7 0.910
4.8 0.5 0.025
19.6 5.2 0.064
rison of heart failure and control groups (Mann-Whitney test).atienters
nts
7 6
oups (Mof HFPara
roup
5–1,83
.9–404
0.1
1.6
0.4
0.1
3,525
146.6
0.5
9.3
compa
osylated hemoglobin A1c; HF heart failure; HOMA-IR homeostasis
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Spontaneous lipolysis. Spontaneous lipolysis at baseline
was evaluated by analyzing DGC in all samples obtained
throughout the last hour of a baseline period. HF patients
had higher spontaneous lipolytic rate by 19% than control
subjects (189.0 37.3 mol/l vs. 152.1 35.1 mol/l, p
.01) (Fig. 1A). Spontaneous lipolysis (DGC in a control
robe) remained unchanged in healthy volunteers, but
ecreased by 22% in the HF group (p  0.01) during the
xperiment period.
esponse to BNP1–32 and norepinephrine. Compared
with baseline DGC, the perfusion with 10 M BNP1–32
increased lipolysis by 2.8  0.5-fold and 3.2  0.3-fold
(both p  0.05) in control and HF subjects, respectively.
he increment in lipolysis induced by 10 M BNP1–32 was
similar between groups (p 0.61). The lipolytic response to
the lower BNP1–32 concentration (0.1 M) differed be-
ween HF and control subjects (p  0.02); lipolysis in-
creased by 17% (p  0.056) in HF subjects, but remained
nchanged in the control group (p  0.39). No differences
ere observed between the HF and control groups (p 
.35) in norepinephrine-induced lipolysis (1.7  0.4-fold
nd 1.7  0.2-fold increase in controls and HF, p  0.04
and p  0.06, respectively). Analysis of absolute differences
in DGC (in mol/l) after BNP1–32 perfusions revealed a
trend toward a higher response in HF than in control
subjects both at low and high BNP1–32 concentrations (by
23% and 41%, respectively, p  0.1 and p  0.07,
respectively). Data are summarized in Figures 2 and 3.
Determinants of spontaneous lipolysis and response to
BNP1–32. Differential regulation of lipolysis was observed
between HF and control groups. Spontaneous DGC was
associated with adiposity and insulin resistance evaluated as
the area under the plasma insulin curve (AUCinsulin) during
the oral glucose tolerance test (r  0.67, p  0.01 and
r  0.88, p  0.01) in the control group, whereas these
associations were absent in the HF subjects (r  0.31,
A B
Figure 1 Spontaneous Adipose Tissue Lipolysis and Blood Flow
(A) Dialysate glycerol concentrations reflecting baseline lipolytic rate in adipose tis
sue blood flow at baseline and after pharmacological stimulation (10 M B-type n
compare values before and after perfusions, and an ordinary t test was used whe
0.05 versus baseline.p  0.5 and r  0.52, p  0.18). No associations were
bserved between basal lipolytic rate and plasma iBNP in
he HF or control group (r  0.41, p  0.24 and r  0.5,
 0.1, respectively) (Fig. 4A). However, lipolytic response
o 10-M BNP1–32 perfusion was inversely related to fat
mass (%) in the HF group (r  0.90, p  0.01), but no
relationship with fat mass or other investigated variables
(fasting plasma insulin, homeostasis model assessment of
insulin resistance, INS120) was observed in the control
roup (Fig. 4B).
hanges in AT blood flow and AT cyclic guanosine mono-
hosphate production during BNP1–32 administration. Blood
flow in AT was evaluated using the ethanol concentration
outflow/inflow ratio, as described previously (14,31). No
differences were observed in the HF and control groups at
baseline or after 10-M BNP1–32 perfusion, which induced
vasodilation in both groups. In contrast, norepinephrine
administration led to vasodilation in control subjects only
(Fig. 1B). Additionally, after the 10-M BNP1–32 perfusion
ontrol and Heart Failure Subjects
B) Changes in ethanol outflow/inflow concentration ratio reflecting adipose tis-
tic peptide [BNP]1–32 and 10 M norepinephrine). A paired t test was used to
aring differences between groups. *p  0.05 between groups, N  5; #p 
Figure 2 Dialysate Glycerol Concentrations
After Pharmacological Stimulation
Values were calculated as the percentage of change in dialysate glycerol con-
centration at time 140 min over averaged values of spontaneous lipolysis
obtained at time points (0 to 80 min). Differences between control and heart
failure (HF) groups were analyzed using a t test. *p  0.05. BNP  B-type
natriuretic peptide.in C
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September 6, 2011:1119–25 BNP-Induced Lipolysis in Heart Failurein a separate group of 4 healthy volunteers, we observed a
43.2 12.8-fold increase (p 0.05) in AT cyclic guanosine
monophosphate concentration that was associated with a
concomitant increase in DGC (r  1, p  0.001). These
esults indicate that cyclic guanosine monophosphate–
ependent lipolytic pathway is activated in adipocytes dur-
ng BNP administration.
iscussion
e present several new findings concerning the regulation
f lipolysis in AT in HF. In nondiabetic advanced HF
A
Figure 3 Dialysate Glycerol Concentrations in Individual Probes
Dialysate glycerol concentrations after stimulation with B-type natriuretic peptide [
(A) Control subjects. (B) Heart failure subjects.
Figure 4 Associations Between Lipolysis Regulation and the B
Association between plasma immunoreactive B-type natriuretic peptide (iBNP) leve
to 10-M B-type natriuretic peptide (BNP) perfusion and fat mass (percentage1–32atients, spontaneous lipolysis is enhanced compared with
ody composition–matched healthy controls. In both
roups, administration of BNP1–32 leads to a strong lipolytic
response. Moreover, the responsiveness of AT to BNP1–32
is not attenuated, but rather increased in HF, and it is
inversely proportional to body fat mass.
Increased spontaneous lipolysis in HF. Humoral factors
including NPs (23), catecholamines (14,32), insulin (33),
and drugs (e.g., beta-blockers) contribute to lipolysis regu-
lation in HF. The finding of increased spontaneous lipolysis
in HF is consistent with a report of increased plasmatic FFA
B
ing Pharmacological Perfusions
32 or norepinephrine. *p  0.05, paired t test.
ystem in Control and HF Subjects
spontaneous lipolysis (A). Association between lipolytic response
y weight) (B). HF  heart failure.Dur
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BNP-Induced Lipolysis in Heart Failure September 6, 2011:1119–25flux in the HF state (1). Lipolysis is physiologically inhibited by
insulin, and altered insulin action thus regulates lipolytic rate.
Indeed, insulin resistance is frequently observed in nondiabetic
HF patients (30). Furthermore, higher plasma insulin levels
during the oral glucose tolerance test (representing a dynamic
test of glucose metabolism) were associated with greater
spontaneous lipolysis in the HF group but not in the control
group in our study, indicating that insulin resistance and the
attenuated antilipolytic effect of insulin might contribute to
greater lipolysis in HF.
BNP1–32 induced strong lipolytic effects in both control
nd HF subjects. The effect of bioactive BNP1–32 on AT
lipolysis of both groups is in line with previous experiments
using local, systemic, or in vitro administration of ANP
(14,34,35). The magnitude of lipolysis induced by 10 M
BNP1–32 is comparable to that observed after administration
f 10 M ANP (14); however, because the subjects in this
tudy differ from the previous in several cofounders (e.g.,
ody composition, age) further BNP1–32 studies are needed
o directly compare in vivo lipolytic potency of ANP and
NP. Importantly, because the effects of catecholamines are
ttenuated in HF by beta-blocker therapy, NPs might be
ven more important regulators of lipolysis in HF subjects
han in control subjects. Despite the fact that HF is often
ssociated with resistance of vascular and renal tissues to the
ffects of NPs due to multiple mechanisms (36), we did not
bserve diminished lipolysis induced by BNP1–32 in the HF
group, suggesting that NP resistance in HF is not ubiqui-
tous in all tissues.
Heightened AT responsiveness to BNP1–32. A perfusion
with 2 concentrations of BNP1–32 allowed us to partly
evaluate the BNP sensitivity of AT. Although the response
was similar in both groups with 10-M perfusion, lipolysis
ctivation with 0.1 M was higher in HF subjects, indicat-
ng increased sensitivity of AT to BNP. How then can most
f the HF patients maintain their stable fat mass, regardless
f a large increase in iBNP? This contradiction could be
xplained by the notion that bioactive BNP species are
ctually deficient in HF subjects (36). Mass spectrometry
nalysis showed that circulating iBNP in HF patients
ontains mostly biologically inactive BNP pro-forms
20,37). Here we show higher AT sensitivity to BNP1–32
despite elevated circulating iBNP and thus provide indirect
in vivo support for the hypothesis of active BNP deficiency
in HF. Additionally, the absence of an association between
iBNP and spontaneous lipolysis in our study further sup-
ports this hypothesis.
Interestingly, we observed an inverse association between
BNP1–32-induced lipolysis and fat mass in HF. In obese
subjects, lower lipolytic responsiveness to NPs and therefore
lower FFA flux may translate into fewer detrimental effects
on cardiac function (5–7) and could underlie a “paradoxical”
association between increased fat mass and better HF
prognosis (38). Increased NP clearance receptors in AT of
obese subjects (39) or the effects of a high-fat diet (40) can
explain lower lipolytic BNP1–32 responses in obese subjects(40). Furthermore, the ability of BNP to regulate whole-
body energy homeostasis (41) via enhanced mitochondrial
biogenesis and lipid oxidation in skeletal muscle (40) might
also modify plasma FFA levels; however, it remains unclear
how these mechanisms are operational in HF. Subse-
quently, AT might become more sensitive to BNP1–32 as
body fat is decreasing (e.g., during the weight loss or in
cardiac cachexia), further perpetuating the vicious cycle of
weight loss.
Effects of BNP1–32 on AT blood flow. Because changes in
T blood flow affect DGC, we evaluated AT blood flow
uring perfusions. Neither AT blood flow at baseline nor
he vasodilatory response to 10 M BNP1–32 differed
between groups. No effect of norepinephrine on AT blood
flow was observed in the HF group, whereas vasodilation
occurred in control subjects.
Study limitations. Our work has identifiable limitations.
First, it was limited to advanced HF in middle-aged men
without diabetes and the number of examined subjects is
rather small. Second, concentrations of BNP1–32 used in
microdialysis perfusions were substantially higher than
physiological levels in AT, and it is thus possible that using
lower doses would provide additional information in a more
physiological range. Third, the HF group was somewhat
older than control subjects. Because aging is typically
associated with diminished lipolysis (33,42), our results
might underestimate the lipolysis of HF compared with
younger controls. Future studies using systemic BNP1–32
infusion at more physiological concentrations are needed to
extend our findings, help to delineate the real cause-and-
effect relationship, and describe other endocrine and meta-
bolic changes induced by BNP (e.g., changes in adipokine
levels and substrate use). Additionally, studies comparing
patients with different HF severity across a range of adipos-
ity and insulin resistance will provide important and clini-
cally relevant information.
Conclusions
Our observations suggest that the lipolytic rate is increased
in patients with HF. Furthermore, induction of lipolysis by
BNP1–32 is increased in HF patients compared with control
ubjects, which suggests that BNP might play an important
ole in excessive FFA mobilization and related metabolic
bnormalities including cardiac cachexia.
Acknowledgments
The authors thank Zuzana Parizkova and Hana Gregorova
for their excellent technical assistance, nurse coordinators
Hana Podlesakova and Josef Halaxa, and Dr. Petr Tuma,
PhD, for his help with biochemical analyses.
Reprint requests and correspondence: Dr. Vojtech Melenovsky,
Department of Cardiology, Institute of Clinical and Experimental
Medicine, Videnska 1958/9, Prague 140 21, Czech Republic.
E-mail: vome@ikem.cz.
22
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
1125JACC Vol. 58, No. 11, 2011 Polak et al.
September 6, 2011:1119–25 BNP-Induced Lipolysis in Heart FailureREFERENCES
1. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and
oxidation in congestive heart failure. Am J Cardiol 1998;81:45–50.
2. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure.
J Am Coll Cardiol 2009;54:1637–46.
3. Nuutila P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle
operates in human heart and skeletal muscle in vivo. J Clin Invest
1992;89:1767–74.
4. Mjos OD. Effect of free fatty acids on myocardial function and oxygen
consumption in intact dogs. J Clin Invest 1971;50:1386–9.
5. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid
accumulation in the failing human heart resembles the lipotoxic rat
heart. FASEB J 2004;18:1692–700.
6. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia:
a systematic overview. Pharmacol Ther 2009;121:227–52.
7. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk
factor for mortality in chronic heart failure. Lancet 1997;349:1050–3.
8. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in
heart failure. Circulation 2007;116:434–48.
9. Lafontan M, Moro C, Berlan M, Crampes F, Sengenès C, Galitzky J.
Control of lipolysis by natriuretic peptides and cyclic GMP. Trends
Endocrinol Metab 2008;19:130–7.
10. Moro C, Crampes F, Sengenès C, et al. Atrial natriuretic peptide
contributes to physiological control of lipid mobilization in humans.
FASEB J 2004;18:908–10.
11. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J.
Natriuretic peptides: a new lipolytic pathway in human adipocytes.
FASEB J 2000;14:1345–51.
12. Polak J, Moro C, Klimcakova E, et al. The atrial natriuretic peptide-
and catecholamine-induced lipolysis and expression of related genes in
adipose tissue in hypothyroid and hyperthyroid patients. Am J Physiol
Endocrinol Metab 2007;293:E246–51.
13. Moro C, Pillard F, De Glisezinski I, et al. Training enhances ANP
lipid-mobilizing action in adipose tissue of overweight men. Med Sci
Sports Exerc 2005;37:1126–32.
14. Moro C, Polak J, Richterova B, et al. Differential regulation of atrial
natriuretic peptide- and adrenergic receptor-dependent lipolytic path-
ways in human adipose tissue. Metabolism 2005;54:122–31.
15. Lamba S, Abraham WT. Alterations in adrenergic receptor signaling
in heart failure. Heart Fail Rev 2000;5:7–16.
16. von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD.
Inflammatory biomarkers in heart failure revisited: much more than
innocent bystanders. Heart Fail Clin 2009;5:549–60.
17. Moro C, Pillard F, De Glisezinski I, et al. Exercise-induced lipid
mobilization in subcutaneous adipose tissue is mainly dependent on
natriuretic peptides in overweight men. Am J Physiol Endocrinol
Metab 2008;295:E505–13.
18. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic
exercise training improves atrial natriuretic peptide and catecholamine-
mediated lipolysis in obese women with polycystic ovary syndrome.
J Clin Endocrinol Metab 2009;94:2579–86.
19. Moro C, Polak J, Hejnova J, et al. Atrial natriuretic peptide stimulates
lipid mobilization during repeated bouts of endurance exercise. Am J
Physiol Endocrinol Metab 2006;290:E864–9.
20. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr.
Biology of the natriuretic peptides. Am J Cardiol 2008;101:3–8.
21. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008:
the Task Force for the Diagnosis and Treatment of Acute and Chronic
Heart Failure 2008 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association of the ESC (HFA)and endorsed by the European Society of Intensive Care Medicine
(ESICM). Eur J Heart Fail 2008;10:933–89.
2. Arner P, Bolinder J. Microdialysis of adipose tissue. J Intern Med
1991;230:381–6.
3. Fellander G, Linde B, Bolinder J. Evaluation of the microdialysis
ethanol technique for monitoring of subcutaneous adipose tissue blood
flow in humans. Int J Obes Relat Metab Disord 1996;20:220–6.
4. Langin D. Adipose tissue lipolysis as a metabolic pathway to define
pharmacological strategies against obesity and the metabolic syn-
drome. Pharmacol Res 2006;53:482–91.
5. Xu-Cai YO, Wu Q. Molecular forms of natriuretic peptides in heart
failure and their implications. Heart 2010;96:419–24.
6. Floras JS. Sympathetic nervous system activation in human heart
failure: clinical implications of an updated model. J Am Coll Cardiol
2009;54:375–85.
7. Heck PM, Dutka DP. Insulin resistance and heart failure. Curr Heart
Fail Rep 2009;6:89–94.
8. Pilz S, Marz W. Free fatty acids as a cardiovascular risk factor. Clin
Chem Lab Med 2008;46:429–34.
9. Pilz S, Scharnagl H, Tiran B, et al. Free fatty acids are independently
associated with all-cause and cardiovascular mortality in subjects with
coronary artery disease. J Clin Endocrinol Metab 2006;91:2542–7.
0. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin
sensitivity as an independent risk factor for mortality in patients with
stable chronic heart failure. J Am Coll Cardiol 2005;46:1019–26.
1. Sengenes C, Stich V, Berlan M, et al. Increased lipolysis in adipose
tissue and lipid mobilization to natriuretic peptides during low-calorie
diet in obese women. Int J Obes Relat Metab Disord 2002;26:24–32.
2. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with
physiological atrial natriuretic peptide concentrations in humans.
J Clin Endocrinol Metab 2005;90:3622–8.
3. Toth MJ, Tchernof A. Lipid metabolism in the elderly. Eur J Clin
Nutr 2000;54 Suppl 3:S121–5.
4. Galitzky J, Sengenès C, Thalamas C, et al. The lipid-mobilizing effect
of atrial natriuretic peptide is unrelated to sympathetic nervous system
activation or obesity in young men. J Lipid Res 2001;42:536–44.
5. Sengenès C, Zakaroff-Girard A, Moulin A, et al. Natriuretic peptide-
dependent lipolysis in fat cells is a primate specificity. Am J Physiol
Regul Integr Comp Physiol 2002;283:R257–65.
6. Chen HH. Heart failure: a state of brain natriuretic peptide deficiency
or resistance or both! J Am Coll Cardiol 2007;49:1089–91.
7. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett
JC Jr., Muddiman DC. Quantitative mass spectral evidence for the
absence of circulating brain natriuretic peptide (BNP-32) in severe
human heart failure. Proc Natl Acad Sci U S A 2005;102:17442–7.
8. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular
disease: risk factor, paradox, and impact of weight loss. J Am Coll
Cardiol 2009;53:1925–32.
9. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma
natriuretic peptide levels. Circulation 2004;109:594–600.
0. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/
cGMP-dependent protein kinase cascades promote muscle mitochon-
drial biogenesis and prevent obesity. Diabetes 2009;58:2880–92.
1. Moro C, Smith SR. Natriuretic peptides: new players in energy
homeostasis. Diabetes 2009;58:2726–8.
2. Klein S, Young VR, Blackburn GL, Bistrian BR, Wolfe RR. Palmitate
and glycerol kinetics during brief starvation in normal weight young
adult and elderly subjects. J Clin Invest 1986;78:928–33.
Key Words: B-type natriuretic peptide y free fatty acids y heart failure
y insulin resistance y lipolysis.
